Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Completes Clinical Trials for its Initial FDA 510(k) Submission

GAITHERSBURG, Md., Feb. 05, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that it has completed the clinical trials needed to support its 510(k) submission for the detection of...
December 18, 2018 07:30 ET | Source: OpGen, Inc.

OpGen Completes CDC Contract to Develop Clinical Support Mobile-Based Tools for Antimicrobial Stewardship and Infection Control

GAITHERSBURG, Md., Dec. 18, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that it has provided the final report for completion of the contract from the Centers for Disease...
December 04, 2018 07:30 ET | Source: OpGen, Inc.

OpGen Receives Regulatory Approval to Market Pathogen Identification Products in Colombia

GAITHERSBURG, Md., Dec. 04, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today it has received approval from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos...
November 13, 2018 16:02 ET | Source: OpGen, Inc.

OpGen Reports third quarter 2018 Financial Results and Provides Business Update

Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Nov. 13, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three...
November 06, 2018 07:30 ET | Source: OpGen, Inc.

OpGen Completes Specimen Accrual and Testing in Acuitas® Clinical Verification Study

Study evaluated potential utility in management of complicated urinary tract infections; Analysis and peer-reviewed manuscript preparation are underway GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE...
November 05, 2018 17:23 ET | Source: OpGen, Inc.

OpGen Announces Date of Third Quarter 2018 Financial Results Conference Call

GAITHERSBURG, Md., Nov. 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that the Company will report financial results for the three and nine months ended September 30, 2018...
October 31, 2018 07:30 ET | Source: OpGen, Inc.

OpGen Collaborates With QIAGEN to Advance Rapid Diagnostics for Antimicrobial Resistant Bacteria

GAITHERSBURG, Md., Oct. 31, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced a collaboration with QIAGEN N.V. to advance rapid diagnostics for antimicrobial resistance (AMR)....
October 18, 2018 08:14 ET | Source: OpGen, Inc.

OpGen Announces Pricing of Public Offering of Common Stock

GAITHERSBURG, Md., Oct. 18, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced the pricing of an underwritten public offering of approximately 2.2 million shares of its common stock...
October 17, 2018 16:18 ET | Source: OpGen, Inc.

OpGen Announces Proposed Public Offering of Common Stock

GAITHERSBURG, Md., Oct. 17, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today announced that it has commenced an underwritten public offering of its common stock. All of the shares are being...
October 15, 2018 17:35 ET | Source: OpGen, Inc.

OpGen Provides Business and Preliminary Financial Update

GAITHERSBURG, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today provided an update on its commercial activities and clinical trials for its Acuitas® AMR Gene Panel tests and...